Skip to content

#阿斯利康

Today 0 items
Oct 15Thu
  1. biospace.com69

    AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro

    AstraZeneca will pay insitro up to $1.5 billion to discover drug targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies using insitro's Virtual Human AI platform. Insitro receives $40 million upfront and up to $1.46 billion in milestones plus royalties, while AstraZeneca advances any candidates through development. The deal adds to AstraZeneca's MASH work, which includes the Phase 1 anti-fibrotic asset AZD2389.

    Why it matters: A large pharma-AI target discovery deal in MASH and cardiomyopathies, indications where AstraZeneca has recent setbacks.

Oct 13Tue
  1. biopharmadive.com40

    Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data

    Bausch + Lomb named board chair Thomas Appio interim CEO after he and Brent Saunders mutually agreed to Saunders' exit, and raised its 2026 earnings outlook. Merck disclosed that proliferative diabetic retinopathy adverse events occurred in 6.7% and 6.1% of remigromig patients versus 0.9% on Lucentis, with the drug not superior on secondary measures. Amgen and AstraZeneca reported nearly 70% of eosinophilic esophagitis patients on Tezspire's highest dose were in remission at 24 weeks; the FDA also approved Asahi Kasei's Hovilpri.

    Why it matters: CEO change at Bausch + Lomb plus pivotal safety and efficacy data on remigromig, Tezspire and a new HSV approval.

Oct 2Fri
  1. biocentury.com44

    Trio of biotechs draw nine-figure fundings: Public Equity Report

    Immix Biopharma (NASDAQ:IMIX) raised $125 million in an offering underwritten by J.P. Morgan, announced minutes after an interim readout from the Phase II NEXICART-2 trial showed its BCMA-targeted CAR-T therapy NXC-201 achieved an 89% complete response rate among 45 patients with light-chain (AL) amyloidosis. Immix plans a BLA submission next year, when final data from the study are expected. Sagimet and Pyxis Oncology also raised nine-figure sums, alongside an AstraZeneca/Summit item.

Sep 30Wed
Sep 29Tue
  1. biospace.com52

    Summit snags $2B investment from AstraZeneca, clearing financial overhang

    AstraZeneca is investing $2 billion in Summit Therapeutics through a direct equity purchase of about 109,000 preferred shares, giving it roughly 12% of Summit's common shares at $18.36 per share, a 10% premium. The deal, expected to close within a week pending regulatory clearances, lifts Summit's cash to an estimated $2.5 billion and leaves it holding full rights to ivonescimab, the PD-1/VEGF bispecific, in its territories. The partners will also start trials pairing AstraZeneca's anti-CLDN18.2 ADC sonesitatug vedotin with ivonescimab in gastrointestinal cancers, while the FDA decides Summit's BLA for the NSCLC drug by Nov. 14.

    Why it matters: Large pharma is paying $2 billion for equity exposure to the PD-1/VEGF class without licensing ivonescimab.

  2. biopharmadive.com48

    AstraZeneca invests $2B in Summit, gaining ‘seat at the table’ for PD-1/VEGF drug push

    AstraZeneca will invest $2 billion in Summit Therapeutics by buying about 109,000 shares of convertible preferred stock, giving it roughly 12% ownership, or about 10.6% fully diluted. The companies will jointly test Summit's PD-1/VEGF drug ivonescimab with AstraZeneca medicines, starting with the ADC "Sone-Ve" in gastrointestinal tumors, and will share development costs while retaining rights to their own drugs. Ionescimab previously halved the risk of progression or death versus Keytruda in a Phase 3 lung cancer study, and the partnership may expand to further combinations.

Aug 24Mon
  1. fiercepharma.com47

    Daiichi Sankyo promotes Ken Keller to lead new commercialization unit

    Daiichi Sankyo has promoted Ken Keller, who has led its global oncology business for five years, to chief commercialization officer of a new globally integrated commercialization unit starting April 1. The restructured organization covers five regions, with internal appointments including Yuichi Yomasu in China, Markus Kosch in Europe, Marcelo Goncalves in Latin America, Kenji Shigeta in North America and Nobuo Murakami in Japan, Asia and the Pacific. The unit supports Daiichi Sankyo's plan to become a top-five oncology company by 2035 and to make five drugs available in 20 new indications by 2030.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org